

This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization.

WORLD HEALTH ORGANIZATION
TECHNICAL REPORT SERIES

No. 384

**WHO EXPERT COMMITTEE ON
BIOLOGICAL STANDARDIZATION**

Twentieth Report

WORLD HEALTH ORGANIZATION

GENEVA

1968

© World Health Organization 1968

Publications of the World Health Organization enjoy copyright protection in accordance with the provisions of Protocol 2 of the Universal Copyright Convention. Nevertheless governmental agencies or learned and professional societies may reproduce data or excerpts or illustrations from them without requesting an authorization from the World Health Organization.

For rights of reproduction or translation of WHO publications *in toto*, application should be made to the Division of Editorial and Reference Services, World Health Organization, Geneva, Switzerland. The World Health Organization welcomes such applications.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the Director-General of the World Health Organization concerning the legal status of any country or territory or of its authorities, or concerning the delimitation of its frontiers.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature which are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

PRINTED IN SWITZERLAND

CONTENTS

	Page
GENERAL	8

PHARMACOLOGICAL

Antibiotics

1. Capreomycin	10
2. Rifamycin SV	10
3. Penicillin	11
4. Phenoxymethylpenicillin	11
5. Lymecycline	11
6. Methacycline	12
7. Candicidin, trichomycin and other heptaene antibiotics	12
8. Other antibiotics	12

MISCELLANEOUS

9. Haemoglobin	12
--------------------------	----

IMMUNOLOGICAL

Antigens

10. Tuberculins	13
11. Rabies vaccine	14
12. Cholera vaccine	14
13. Newcastle disease vaccine (live)	14
14. Cardiolipin and lecithin (egg)	15
15. Influenza virus haemagglutinin (type A)	15
16. Anthrax vaccine (inactivated)	16
17. Rubella haemagglutinin	16

Antibodies	Page
18. Anti- <i>Brucella abortus</i> serum	16
19. Anti-Newcastle-disease serum	17
20. Anti-smallpox serum	17
21. Anti-anthrax serum	17
22. Anti-A blood-typing sera	17
23. Anti-toxoplasma serum	18
24. Anti-canine-distemper serum	18
25. Anti-canine-hepatitis serum	19
26. Anti- <i>Salmonella pullorum</i> sera	19
27. Anti- <i>Mycoplasma gallisepticum</i> serum	19
28. Anti-rubella serum	19

BIOLOGICAL REFERENCE REAGENTS

29. Anti-trichinella human serum	20
30. Cholera agglutinating sera	20
31. Adenovirus antisera	21
32. Respiratory virus and <i>Mycoplasma pneumoniae</i> antisera	21

REQUIREMENTS FOR BIOLOGICAL SUBSTANCES

33. Requirements for tuberculins	21
34. Requirements for inactivated influenza vaccine	22
35. Requirements for other biological substances	22

ANNEXES

Annex 1. Requirements for tuberculins (Requirements for biological substances No. 16)	23
Annex 2. Requirements for inactivated influenza vaccine (Requirements for biological substances No. 17)	43
Annex 3. Requirements for biological substances (general description and list of published documents)	57
Annex 4. International biological standards and international biological reference preparations, 1968	59

	Page
Annex 5. International biological reference reagents	88
Annex 6. Proposed international biological standards, international biological reference preparations and international biological reference reagents	94
Annex 7. Discontinued international biological standards	98
INDEX	99



WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Geneva, 25-30 September 1967

Members :

- Dr D. R. Bangham, Director, Division of Biological Standards, National Institute for Medical Research, Mill Hill, London, England
- Dr H. H. Cohen, Director, Rijks Instituut voor de Volksgezondheid, Utrecht, Netherlands
- Dr J. Desbordes, Director, Division of Microbiology, National Public Health Laboratory, Paris, France (*Vice-Chairman*)
- Dr C. Hamburger, Chief, Hormone Department, Statens Seruminstitut, Copenhagen, Denmark
- Dr T. B. Jabloková, Head, BCG and Tuberculin Laboratory, Tarasevič State Institute for the Control of Medico-Biological Preparations, Moscow, USSR
- Dr P. Krag, Director, Department of Biological Standards, Statens Seruminstitut, Copenhagen, Denmark
- Dr R. Murray, Director, Division of Biologics Standards, National Institutes of Health, Bethesda, Md., USA
- Dr J. B. Shrivastav, Deputy Director-General of Health Services, New Delhi, India
- Mr J. R. Thayer, National Biological Standards Laboratory, Parkville, Australia (*Rapporteur*)
- Professor A. E. Wilhelmi, Department of Biochemistry, Division of Basic Health Sciences, Emory University, Atlanta, Ga, USA (*Chairman*)

Representatives of other organizations :

Food and Agriculture Organization of the United Nations :

- Mr I. Davidson, Senior Research Officer, Central Veterinary Laboratory, Weybridge, Surrey, England

Secretariat :

- Professor D. G. Evans, London School of Hygiene and Tropical Medicine, London, England (*Consultant*)
- Mr E. C. Hulse, Director, Department of Biological Products and Standards, Central Veterinary Laboratory, Weybridge, Surrey, England (*Consultant*)
- Dr A. N. Klimov, Director, Division of Biomedical Sciences, WHO, Geneva
- Mr J. W. Lightbown, Division of Biological Standards, National Institute for Medical Research, Mill Hill, London, England (*Consultant*)
- Dr B. Lunenfeld, Institute of Endocrinology, Tel-Hashomer Government Hospital and Bar-Ilan University, Tel-Hashomer, Israel (*Consultant*)
- Dr A. S. Outschoorn, Chief Medical Officer, Biological Standardization, WHO, Geneva (*Secretary*)
- Dr J. Spaun, Deputy Director, Department of Biological Standards, Statens Seruminstitut, Copenhagen, Denmark (*Consultant*)
- Dr W. W. Wright, Deputy Director, Division of Antibiotics and Insulin Certification, Bureau of Science, Food and Drug Administration, Washington, USA (*Consultant*)

WHO EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION

Twentieth Report

The WHO Expert Committee on Biological Standardization met in Geneva from 25 to 30 September 1967. Dr P. Dorolle, Deputy Director-General, on behalf of the Director-General, welcomed the members of the Committee. He also welcomed the representative of the Food and Agriculture Organization of the United Nations.

He recalled that the Expert Committee on Biological Standardization had been first convened by the Interim Commission and it was, therefore, among the oldest Committees of the Organization. The agenda this year included a number of pharmacological substances (antibiotics and hormones) as well as immunological substances (antigens and antibodies). Many of the latter were primarily of veterinary interest, an indication of the growing importance of substances used in veterinary medicine. This is also reflected in the increasing amount of work handled by the third International Laboratory for Biological Standards. He mentioned that, in recent years, the field of biological standardization had been expanding in a number of directions of interest to clinical diagnosis and research. There were perhaps several substances intended for such purposes that were not characteristic of those traditionally associated with this Committee. He emphasized that the work of the Committee in those areas should be related to the developing programme of work of WHO, which would continue to make available to Member States whatever facilities and services it could provide. National institutions would, however, have to be depended upon to make the necessary studies preliminary to the work being continued under the auspices of this Expert Committee.

As in previous years, the Committee would also be asked to examine certain sets of requirements for biological substances, drafted by the WHO Secretariat, from the point of view of their suitability for international use, i.e., to help countries to ensure the efficacy and safety of these biological substances when used in prophylaxis and therapy.

GENERAL

The Committee considered some general questions relating to the standardization of certain hormones.¹ A number of new and urgent problems have arisen in connexion with recent developments in endocrinology. The application of techniques of radioimmunoassay, several orders of magnitude more sensitive than most current bioassays, makes possible the detection and measurement of protein and polypeptide hormones in human plasma and body fluids. These methods offer for the first time an opportunity for studies of certain at present very poorly understood aspects of the regulation of metabolism, the physiology of growth and, especially, the physiology of reproduction in man. Applications in animal husbandry, of importance to world economy and to human nutrition and health, are also foreseeable. The feasibility of the methods has been adequately demonstrated and a large international interest exists. The rate of work is limited, however, not only by certain difficulties in obtaining suitable materials for general use, but also by the lack of international standards for use in immunoassays. Such standards would improve the comparability of the results of assays of the hormones obtained in different laboratories. The provision of suitable standards, however, poses certain problems, peculiar to the field of hormones.

The technique of immunoassay involves a method for estimating hormones in which specific antigen-antibody interactions not previously used for the assay of these substances are paramount. It is not yet clear how measurements of hormone antigen are to be related to biological activity. Although where highly purified hormones are used, a systematic correlation between the results of biological assays and immunoassays might be expected, this is not necessarily so when, for reasons of stability or scarcity, less pure materials must be employed. Because of these difficulties, a standard for a hormone antigen for use in immunoassay may be essential in order to reduce the variation of estimates of the same test materials in different laboratories. The collaborative assay for the establishment of such an antigen standard should be designed to demonstrate fulfilment of this purpose.

Since the process in immunoassay is essentially the reaction between a specific antibody and its antigen, what is estimated is the amount of immuno-reactive material present in the unknown sample. The antigen standard for such an assay should resemble as nearly as possible the native hormone. Ideally, where the standard is a very highly purified preparation, the results can be expressed in terms of weight of the antigen standard per unit volume of sample, or in terms of defined international units. Either method suffices because it provides a figure that is correlated with biological activity,

¹ WHO Technical Report Series, No. 20, 1956, p. 100.

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_30864

